)
Visual
test
Puma Biotechnology
Puma Biotechnology (PBYI) investor relations material
Puma Biotechnology Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Q3 2025 total revenue was $54.5M, down from $80.5M in Q3 2024, mainly due to lower royalty and international product revenue, while U.S. NERLYNX sales volume rose 8% year-over-year to $51.9M, offsetting declines elsewhere.
Net income for Q3 2025 was $8.8M ($0.18 per basic share), up from $5.9M in Q2 2025 but down from $20.3M in Q3 2024; non-GAAP net income was $10.5M ($0.21 per share).
2,949 ex-factory bottles sold in Q3 2025, up 13% quarter-over-quarter and 8% year-over-year; 77% of patients started at a reduced dose.
Clinical progress continues for alisertib in breast and lung cancer, with interim analyses expected in H1 2026.
International expansion continued with new NERLYNX launches in Thailand, Lebanon, and Libya in 2024–2025.
Financial highlights
Net product revenue for Q3 2025 was $51.9M, down from $56.1M in Q3 2024 but up from $49.2M in Q2 2025; royalty revenue was $2.6M, down from $24.4M in Q3 2024.
Cost of sales for Q3 2025 was $12.2M, including $2.4M in amortization of intangible assets, down from $29.1M in Q3 2024.
SG&A expenses for Q3 2025 were $16.8M, down from $18M in Q2 2025 and flat year-over-year; R&D expenses were $15.9M, up from $12.6M in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $94.4M as of September 30, 2025.
Net cash provided by operating activities for the first nine months of 2025 was $27.4M, up from $23.3M in 2024.
Outlook and guidance
Full-year 2025 revenue guidance raised to $220–$223M, with net product revenue of $198–$200M and royalty revenue of $22–$23M.
Full-year 2025 net income guidance increased to $27–$29M; Q4 2025 net product revenue expected at $54–$56M.
SG&A expenses anticipated to decrease 7–10% in 2025; R&D expenses to rise 20–25% due to faster clinical trial enrollment.
Management believes cash and future sales are sufficient to meet operating needs for at least one year.
Key clinical milestones for alisertib trials expected in H1 2026.
How do China's regulatory shifts affect royalties?
Alisertib Phase 3 funding while profitable?
Why are NERLYNX demand and NRx diverging?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebNOV
Q4 revenue up 5% sequentially; strong cash flow and shareholder returns, but 2026 outlook cautious. - 5 FebGL
Earnings and premium growth drive higher 2026 guidance and continued share repurchases. - 5 FebARES
AUM up 29% to $622.5B, with record fundraising, earnings growth, and a 20% dividend hike. - 5 FebSKEL
NAV per share reached ISK 22.4, profit was ISK 4,297m, and a ISK 6,000m dividend was paid. - 5 FebCRNO
Advancing HDAC inhibitors for rare cardiopulmonary diseases, targeting major market and partnership milestones. - 5 Feb035760
Operating profit doubled YOY in Q4 2025, led by digital and global content growth. - 5 Feb033780
Record revenue, profit, and shareholder returns driven by global expansion and real estate growth. - 5 FebCMS
2025 adjusted EPS up 8%+ to $3.61, beating guidance, with a $24B capital plan and higher 2026 outlook. - 5 FebBTU
Q4 net income fell, but Centurion ramp-up and U.S. demand support future growth. - 5 FebFGA
Record Q3 revenue and strong backlog support positive outlook despite operational risks.
Next Puma Biotechnology earnings date
Q4 202526 Feb, 2026
Puma Biotechnology
Next Puma Biotechnology earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Puma Biotechnology Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of cancer. The company specializes in targeted oncology, developing drugs that aim to improve outcomes for patients with specific types of cancer by addressing unmet medical needs. It collaborates with healthcare professionals, researchers, and regulatory bodies to advance its clinical and commercial objectives. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage